Since radiotherapy agents can effectively induce apoptosis through generation of ROS [97] it was observed that specific PI3K inhibitor such as NVP-BKM120 can be used in SqCC to decrease Nrf2 protein levels and sensitize NFE2L2 or KEAP1-mutant cells to radiation [94]. KRAS gene mutations occur approximately in 20–30% of NSCLCs and confer to cancer cells resistance and survival [98, 99]. This evidence concerns the gene KEAP1 and cancer.